Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 in High Cardiovascular Risk Participants
2022-502781-24-00Phase 4Withdrawn
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 20
01
Overview
Phase 4, randomised, double-blind trial in atherosclerotic disease, coronary arteriosclerosis, atherosclerotic cerebrovascular disease and 2 more comparing MK-0616 with Placebo (2 arms). Primary endpoint: CHD death-based MACE plus. Planned start Nov 2023; status: withdrawn.
02
Drugs
enlicitide
03
Conditions
atherosclerotic diseasecoronary arteriosclerosisatherosclerotic cerebrovascular diseasearteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502781-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502781-24-00.